SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
TargeGen announces initiation of clinical trial of JAK2 inhibitor TG101348 in myeloproliferative disease patients
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.